The global PDX (patient-derived xenograft) model market is experiencing robust growth driven by the increasing prevalence of cancer worldwide and the growing demand for personalized medicine. PDX models, which involve implanting patient tumor tissues into immunodeficient mice, have emerged as invaluable tools for preclinical cancer research, offering a more clinically relevant model for studying tumor biology and evaluating drug efficacy. The market is further propelled by the rising adoption of PDX models in drug discovery and development, as they enable researchers to study tumor heterogeneity, metastasis, and drug resistance, leading to the development of more effective cancer therapies. Moreover, advancements in PDX model development, such as the use of 3D culture systems and co-implantation of human immune cells, are enhancing the utility and relevance of these models in translational research.
Global Patient Derived Xenograft (PDX) Models Market was valued at USD 142,396.93 million in 2021 and is expected to reach USD 500,362.17 million by 2029, registering a CAGR of 17.01% during the forecast period of 2022-2029.
To know more, visit https://www.databridgemarketresearch.com/reports/global-pdx-models-market
Below are the Top Five Patient Derived Xenograft (PDX) Models Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
crown bioscience inc. (A subsidiary of JSR Life Sciences, LLC)
|
Crown Bioscience Inc. is a global drug discovery and development services company that specializes in providing preclinical research services using Patient-Derived Xenograft (PDX) models. These models are derived from patient tumor tissues and are used to study cancer biology, evaluate drug efficacy, and personalize treatment approaches. Crown Bioscience offers a wide range of services, including PDX model development, tumor engraftment, drug efficacy testing, and biomarker analysis. The company's expertise in PDX models allows pharmaceutical and biotechnology companies to accelerate their drug discovery and development programs, leading to faster and more effective treatments for cancer patients.
|
|
North America, Europe, China and Taiwan
|
In April 2020, Crown Bioscience Inc. acquired unique models from Leading Academic Medical Centres, the company agreed with Dana-Farber Cancer Institute and the University of Washington. This helped in the product expansion of the company and provided support to the oncology drug development community.
|
|
2.
|
the jackson laboratory
|
The Jackson Laboratory (JAX) is a leading nonprofit biomedical research institution and provider of PDX (Patient-Derived Xenograft) models for cancer research. Founded in 1929, JAX is headquartered in Bar Harbor, Maine, with facilities in Sacramento, California, and Farmington, Connecticut. JAX is renowned for its expertise in genetics, genomics, and cancer research, making it a pivotal player in advancing personalized medicine and cancer therapeutics. JAX's PDX models are derived from patient tumors and engrafted into immunodeficient mice, allowing researchers to study tumor growth, metastasis, and treatment response in a more clinically relevant context. JAX offers a diverse range of PDX models representing various cancer types and genetic backgrounds, making them valuable tools for drug discovery, biomarker identification, and precision medicine.
|
|
U.S. and China
|
In April 2021, Jackson Laboratory and European Bioinformatics Institute created the first cancer research portal for PDX models. By using these models, researchers can better understand a drug reaction in the patient, which is patient-specific, too. This has provided a wide variety of models in one place quickly.
|
|
3.
|
champions oncology, inc.
|
Champions Oncology, Inc. is a leading global company specializing in the development and use of Patient-Derived Xenograft (PDX) models for oncology research. Founded in 2007 and headquartered in Hackensack, New Jersey, Champions Oncology is dedicated to transforming drug discovery and development through innovative approaches to preclinical testing. Champions Oncology's PDX models are derived from patient tumor samples and engrafted into immune-deficient mice, allowing researchers to study tumor growth and response to treatment in a setting that closely mimics the human body. These models are valuable tools for evaluating drug efficacy, identifying biomarkers, and personalizing cancer treatment strategies.
|
|
U.S., Taiwan, U.K. and China
|
In June 2018, Champions Oncology, Inc. recently announced its partnership with Puma Biotechnology and NSABP Foundation, Inc. for the development of patient-derived xenograft models in two multi-center co-clinical trials. This partnership could be an advancement in understanding the sensitivity of cancers. Hence, leading more efficient in providing services to the customers in the segment.
|
|
4.
|
Charles River Laboratories
|
Charles River Laboratories International, Inc. is a prominent global company that provides essential products and services to help expedite the discovery, development, and safe manufacture of new drug therapies. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River is a leading provider of preclinical and clinical laboratory services, including a comprehensive suite of PDX (patient-derived xenograft) models for oncology research. Charles River's PDX models are created by implanting patient tumor tissues into immune-deficient mice, allowing researchers to study tumor growth, metastasis, and response to treatment in a clinically relevant setting. These models play a crucial role in advancing cancer research and drug development by providing valuable insights into tumor biology and therapeutic efficacy.
|
|
U.S., Europe, Asia- Pacific
|
In October 2017, Charles River Laboratories announced its partnership with InSphero AG, which is one of the most efficient leading suppliers of 3D solutions. This partnership could license its partnership of PDX tumors to InSphero. This has indirectly improved the company's preclinical services.
|
|
5.
|
wuxi apptec
|
WuXi AppTec is a leading global pharmaceutical and biotechnology company that provides a wide range of R&D and manufacturing services to support the development of new drug therapies. WuXi AppTec offers a comprehensive suite of services for drug discovery and development, including PDX (patient-derived xenograft) models for oncology research. These models are created by implanting patient tumor tissues into immune-deficient mice, allowing researchers to study tumor growth, metastasis, and response to treatment in a clinically relevant setting. WuXi AppTec's PDX models are valuable tools for evaluating drug efficacy, identifying biomarkers, and personalizing cancer treatment strategies.
|
|
North America, Europe, Asia-
|
In January 2024, WuXi AppTec, a global provider of R&D and manufacturing services for the pharmaceutical, biotech, and medical device industries, announced the commissioning of two new peptide manufacturing plants. One plant is located at its Changzhou facility, while the other is at the new Taixing site in China. This expansion has significantly increased the company's Solid-Phase Peptide Synthesis (SPPS) total reactor volume to 32,000 liters in response to the growing global demand for peptide therapeutics.
|
Conclusion
The global PDX (patient-derived xenograft) market is poised for significant growth and innovation, driven by the increasing demand for personalized cancer therapies and the need for more clinically relevant preclinical models. The market is witnessing advancements in PDX model development, including the use of 3D culture systems and human immune cell co-implantation, which are enhancing the utility and accuracy of these models in cancer research. Key players in the market are expanding their PDX model offerings and investing in research to meet the evolving needs of the oncology research community. Overall, the global PDX models market presents ample opportunities for growth and collaboration, with the potential to revolutionize the development of new cancer therapies and improve patient outcomes.
